

TABLE OF CONTENTS

CONTENTS	PAGE NO.
I. INTRODUCTION	1 - 12
II. REVIEW OF LITERATURE	13 - 82
I. HISTORICAL ASPECTS	13
II. MEASLES EPIDEMIOLOGY	16
A. Agent : The Measles Virus	16
B. Host	19
III. MEASLES VACCINES	36
A. Development	36
B. Types	38
C. Stability and Storage	39
D. Dosage	40
E. Route of Administration	41
F. Reactions to Measles Vaccine	43
G. Contra-indications	48
H. Acceptance	49
I. Measles Vaccine with Multiple Antigens	49
J. Safety	50
K. Optimum Age for Vaccination	50
L. Malnutrition and Vaccination	61
M. Vaccine Efficacy and Strategy	62
N. Aerosolised Vaccine	72
O. Indigenous Vaccine Production	75
P. Future of Measles in Highly Immunised Populations	76
Q. Need for and Prospects of Worldwide Measles Control	76
R. The Remaining Research Needs	77
S. Current Measles Vaccine Strategy	79

<u>CONTENTS</u>	<u>PAGE NO.</u>
IV JUSTIFICATION FOR THE PRESENT STUDY	81
III. MATERIAL AND METHODS	83 - 98
I. EPIDEMIOLOGICAL STUDY	83
A. Baseline Survey	85
B. Follow Up Survey	86
II. SEROLOGICAL STUDY	86
A. Maternal vs. Cord Blood Study	86
B. Waning of Passive Antibody Study	87
C. Seroconversion Study	88
D. Methodology	88
IV. RESULTS, OBSERVATIONS AND DISCUSSION	99 - 169
I. EPIDEMIOLOGICAL STUDY	99
A. Baseline Survey	99
B. Follow Up Survey	109
II. SEROLOGICAL STUDY	120
A. Maternal vs. Cord Blood Study	120
B. Waning of Passive Antibody Study	128
C. Seroconversion Study	141
V. SUMMARY, CONCLUSIONS AND RECOMMENDATIONS	170 - 179
VI. BIBLIOGRAPHY	180 - 208
ANNEXURES	